<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> therapy improves insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in patients with uncomplicated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD), <z:chebi fb="105" ids="17234">glucose</z:chebi> is an important source of energy and preserved myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake is essential for the viability of jeopardized myocardium </plain></SENT>
<SENT sid="2" pm="."><plain>The aim was to test whether <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> changes myocardial metabolism in type 2 diabetic patients with CAD </plain></SENT>
<SENT sid="3" pm="."><plain>We studied 54 patients (38 men and 16 women) with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (HbA(1c) 7.2 + 0.9%) and CAD </plain></SENT>
<SENT sid="4" pm="."><plain>Myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake was measured with [(18)F]fluoro-2-deoxy-d-<z:chebi fb="105" ids="17234">glucose</z:chebi> <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography in ischemic (evaluated by single-<z:chebi fb="23" ids="30212">photon</z:chebi> emission tomography and coronary angiography) and nonischemic regions during euglycemic-hyperinsulinemic clamp before and after a 16-week intervention period with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (n = 27) or placebo (n = 27) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> significantly improved glycemic control (P &lt; 0.0001) and whole-body insulin sensitivity (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> increased myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake from 20.6 +/- 11.8 to 25.5 +/- 12.4 micromol  </plain></SENT>
<SENT sid="7" pm="."><plain>100 g(-1)  </plain></SENT>
<SENT sid="8" pm="."><plain>min(-1) (P = 0.038 vs. baseline, P = 0.023 vs. placebo) in ischemic regions and from 21.7 +/- 12.1 to 28.0 +/- 12.7 micromol  </plain></SENT>
<SENT sid="9" pm="."><plain>100 g(-1)  </plain></SENT>
<SENT sid="10" pm="."><plain>min(-1) (P = 0.014 vs. baseline, P = 0.003 vs. placebo) in nonischemic regions </plain></SENT>
<SENT sid="11" pm="."><plain>The increase in myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake was partly explained by the suppression of free fatty acid levels during clamp </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> therapy significantly <z:mp ids='MP_0002891'>increased insulin sensitivity</z:mp> and improved myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in type 2 diabetic patients with CAD </plain></SENT>
<SENT sid="13" pm="."><plain>These results suggest that <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> therapy may facilitate myocardial <z:chebi fb="105" ids="17234">glucose</z:chebi> storage and utilization in these patients </plain></SENT>
</text></document>